α-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 6, 2005, Pages 1418-1423

  Witkiewicz, Agnieszka K ^a   Varambally, Sooryanarayana ^b   Shen, Ronglai ^c   Mehra, Rohit ^b   Sabel, Michael S ^b,c   Ghosh, Debashis ^c   Chinnaiyan, Arul M ^b,c   Rubin, Mark A ^a   Kleer, Celina G ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CARCINOMA IN SITU; CELL GRANULE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LOCALIZATION; EPITHELIUM CELL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MITOCHONDRION; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FIBROCYSTIC BREAST DISEASE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; RACEMASES AND EPIMERASES; REPRODUCIBILITY OF RESULTS;

EID: 20444406074     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0607     Document Type: Article

References (35)

1. Ronco A, De Stefani E, Mendilaharsu M, Deneo-Pellegrini H. Meat, fat and risk of breast cancer: a case-control study from Uruguay. Int J Cancer 1996;65:328-31.
2. Richardson S, Gerber M, Cenee S. The role of fat, animal protein and some vitamin consumption in breast cancer: a case control study in southern France. Int J Cancer 1991;48:1-9.
3. Mobley JA, Leav I, Zielie P, et al. Branched fatty acids in dairy and beef products markedly enhance α-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Cancer Epidemiol Biomarkers Prev 2003;12: 775-83.
4. Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 2001;10:3-8.
5. Amery L, Fransen M, De Nys K, Mannaerts GP, Van Veldhoven PP. Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase in humans. J Lipid Res 2000;41:1752-9.
6. Rubin MA, Zhou M, Dhanasekaran SM, et al. α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
7. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26:1588-96.
8. Jiang Z, Woda BA, Yang XJ. α-Methylacyl coenzyme A racemase as a marker for prostate cancer. JAMA 2002;287:3080-1; author reply 3081.
9. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol 2004;121:99-107.
10. Jiang Z, Fanger GR, Woda BA, et al. Expression of α-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 2003;34:792-6.
11. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. α-Methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003;27:1128-33.
12. Kuefer R, Varambally S, Zhou M, et al. α-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002;161:841-8.
13. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
14. Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64:6854-7.
15. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495-503.
16. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;163:1445-8.
17. Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 2004;64:8773-7.
18. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003;63:6244-51.
19. Weaver DL, Krag DN, Manna EA, Ashikaga T, Harlow SP, Bauer KD. Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. Mod Pathol 2003;16:1159-63.
20. Laitakari J, Harrison D, Stenback F. Automated image analysis of proliferating cells in carcinoma of the larynx. Acta Otolaryngol 2003;123:759-66.
21. Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004;10:1392-400.
22. Pierga JY, Bonneton C, Magdelenat H, et al. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 2003;89:539-45.
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
24. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160:579-84.
25. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
26. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-81.
27. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
28. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. α-Methylacyl- CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002;26:926-31.
29. Luo J, Zha S, Gage WR, et al. α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6.
30. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68:2142-9.
31. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71:2507-14.
32. Jiang Z, Fanger GR, Banner BF, et al. A dietary enzyme: α-Methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev 2003;27:422-6.
33. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR-γ. Mol Cell 1998;1:465-70.
34. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003;9:1-9.
35. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiorropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.